MedPath

Evaluation of efficacy and safety in bFGF injection to treat severe vocal fold lesions and vocal fold paralysis.

Not Applicable
Conditions
vocal fold atrophy,vocal fold sulcus,vocal fold scars,vocal fold paralysis
Registration Number
JPRN-UMIN000019347
Lead Sponsor
Tokyo Voice Center, International University of Health and Welfare
Brief Summary

Results: No adverse events were recorded. Significant improvements were observed in the maximum phonation time (MPT) and Voice Handicap Index (VHI) after treatment. Multiple injections achieved additional effects. Conclusions and significance: bFGF injection may be a safe and suitable office-based surgery for the alleviation of hoarseness caused by SV based on this preliminary short-term study.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

The subjects with obvious decrease in cardiac function, respiratory function, or hepatic dysfunction in preoperative examinations such as blood sampling, electrocardiogram, or chest x-ray within 3 months. The subjects with vital signs such as heart rate, blood oxygen saturation, and blood pressure are abnormal on the day of surgery. The subjects with other laryngeal disease. The subjects with a history of laryngeal cancer The subjects with drug allergy

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of Phonological Outcome
Secondary Outcome Measures
NameTimeMethod
Improvement of vocal fold vibration Improvement of Aerodynamic assessment
© Copyright 2025. All Rights Reserved by MedPath